×
About 2,460 results

ALLMedicine™ Beta-thalassemia Center

Research & Reviews  1,205 results

Left ventricular systolic dyssynchrony index and endothelial dysfunction parameters as ...
https://doi.org/10.1111/echo.15067
Echocardiography (Mount Kisco, N.Y.); Solmaz H, Cabuk AK et. al.

May 4th, 2021 - Cardiovascular iron load is the leading cause of morbidity and mortality in beta-thalassemia major (β-TM). However, many patients remain asymptomatic until the late stage. In this cross-sectional study, we investigated the role of three-dimensiona...

Drug safety in thalassemia: lessons from the present and directions for the future.
https://doi.org/10.1080/14740338.2021.1919081
Expert Opinion on Drug Safety; Grech L, Sultana J et. al.

Apr 20th, 2021 - Introduction: Beta-thalassemia is an autosomal recessive hereditary anemia characterized by reduced or absent β-globin chain synthesis, affecting about 60,000 people peryear. Management for β-thalassemia major includes regular blood transfusions f...

The power of three-dimensional printing technology in functional restoration of rare ma...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040235
Journal of Medical Case Reports; Oren D, Dror AA et. al.

Apr 13th, 2021 - Thalassemia is an inherited autosomal recessive blood disorder causing abnormal formation of hemoglobin, known as a syndrome of anemia with microcytic erythrocytes. It is the most common genetic disorder worldwide, with a high prevalence among ind...

Detection of Renal Insufficiency in a Cohort of Patients With Beta-thalassemia Major Us...
https://doi.org/10.1097/MPH.0000000000002171
Journal of Pediatric Hematology/oncology; Hamdy M, Shaheen I et. al.

Apr 12th, 2021 - With increased life expectancy among patients with beta-thalassemia major (β-TM) renal insufficiency has been frequently noted because of the persistence of anemia, iron overload and some drug side effects. Serum creatinine becomes elevated in lat...

Free Tissue Transfer in a Patient With Hemoglobin S-Beta-Thalassemia Disease and Mandib...
https://doi.org/10.1177/01945998211002107
Otolaryngology--head and Neck Surgery : Official Journal ... Chang K, Bollig C et. al.

Mar 23rd, 2021 - Free Tissue Transfer in a Patient With Hemoglobin S-Beta-Thalassemia Disease and Mandibular Osteomyelitis.|2021|Chang K,Bollig C,Sclaroff A,Pipkorn P,|

see more →

Guidelines  1 results

Cardiovascular Function and Treatment in Beta-Thalassemia Major
https://www.ahajournals.org/doi/abs/10.1161/CIR.0b013e31829b2be6?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
Pennell, D.,et al.

Jun 30th, 2013 - This aim of this statement is to report an expert consensus on the diagnosis and treatment of cardiac dysfunction in ?-thalassemia major (TM). This consensus statement does not cover other hemoglobinopathies, including thalassemia intermedia and s.

see more →

Drugs  2 results see all →

Clinicaltrials.gov  1,221 results

Left ventricular systolic dyssynchrony index and endothelial dysfunction parameters as ...
https://doi.org/10.1111/echo.15067
Echocardiography (Mount Kisco, N.Y.); Solmaz H, Cabuk AK et. al.

May 4th, 2021 - Cardiovascular iron load is the leading cause of morbidity and mortality in beta-thalassemia major (β-TM). However, many patients remain asymptomatic until the late stage. In this cross-sectional study, we investigated the role of three-dimensiona...

Drug safety in thalassemia: lessons from the present and directions for the future.
https://doi.org/10.1080/14740338.2021.1919081
Expert Opinion on Drug Safety; Grech L, Sultana J et. al.

Apr 20th, 2021 - Introduction: Beta-thalassemia is an autosomal recessive hereditary anemia characterized by reduced or absent β-globin chain synthesis, affecting about 60,000 people peryear. Management for β-thalassemia major includes regular blood transfusions f...

The power of three-dimensional printing technology in functional restoration of rare ma...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040235
Journal of Medical Case Reports; Oren D, Dror AA et. al.

Apr 13th, 2021 - Thalassemia is an inherited autosomal recessive blood disorder causing abnormal formation of hemoglobin, known as a syndrome of anemia with microcytic erythrocytes. It is the most common genetic disorder worldwide, with a high prevalence among ind...

Detection of Renal Insufficiency in a Cohort of Patients With Beta-thalassemia Major Us...
https://doi.org/10.1097/MPH.0000000000002171
Journal of Pediatric Hematology/oncology; Hamdy M, Shaheen I et. al.

Apr 12th, 2021 - With increased life expectancy among patients with beta-thalassemia major (β-TM) renal insufficiency has been frequently noted because of the persistence of anemia, iron overload and some drug side effects. Serum creatinine becomes elevated in lat...

Free Tissue Transfer in a Patient With Hemoglobin S-Beta-Thalassemia Disease and Mandib...
https://doi.org/10.1177/01945998211002107
Otolaryngology--head and Neck Surgery : Official Journal ... Chang K, Bollig C et. al.

Mar 23rd, 2021 - Free Tissue Transfer in a Patient With Hemoglobin S-Beta-Thalassemia Disease and Mandibular Osteomyelitis.|2021|Chang K,Bollig C,Sclaroff A,Pipkorn P,|

see more →

News  31 results

New Gene Therapy Vector Promising for Sickle Cell, Beta-Thalassemia
https://www.medscape.com/viewarticle/945626

Feb 10th, 2021 - NEW YORK (Reuters Health) - A new lentiviral gene therapy vector, ALS20, triggers more hemoglobin production at a lower dose than vectors currently used in trials of blood disorders such as sickle cell disease and beta-thalassemia, researchers say...

Quercetin may reduce iron overload in beta-thalassemia major
https://www.mdedge.com/hematology-oncology/article/207259/bleeding-disorders/quercetin-may-reduce-iron-overload-beta?channel=39313
Caleb Rans

Aug 28th, 2019 - Combination quercetin and desferrioxamine could decrease iron overload in patients with transfusion-dependent beta-thalassemia major, according to a randomized clinical study. Over the course of treatment, quercetin was well tolerated and no major.

Novel conditioning regimen shows benefit for beta-thalassemia major
https://www.mdedge.com/hematology-oncology/article/207231/bleeding-disorders/novel-conditioning-regimen-shows-benefit-beta?channel=341
Caleb Rans

Aug 28th, 2019 - A novel transplant protocol (WZ-14-TM) improved survival outcomes and rates of graft-versus-host disease (GVHD) in patients with beta-thalassemia major undergoing hematopoietic stem cell transplant (HSCT) from an unrelated donor, according to find.

Luspatercept Reduces Blood Transfusions in MDS and Beta-Thalassemia
https://www.medscape.com/viewarticle/905867

Dec 1st, 2018 - SAN DIEGO — The investigational drug luspatercept (under development by Acceleron and Celgene) has been shown to reduce the need for blood transfusions in two separate patient populations. The product, a first-in-class erythroid maturation agent t...

Blood disorders researcher is finalist for Trailblazer Prize
https://www.mdedge.com/hematology-oncology/article/173229/bleeding-disorders/blood-disorders-researcher-finalist
Mary Ellen Schneider

Aug 22nd, 2018 - Daniel Bauer, MD, PhD, a pediatric hematologist and blood disorders researcher in Boston, is one of three finalists for the inaugural Trailblazer Prize for Clinician-Scientists, which is awarded by the Foundation for the National Institutes of Hea.

see more →